Prothena Corp. (PRTA) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Wall Street ends higher as tech rebounds before Nvidia results
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
- Nvidia Q2 preview: a beat is a fail, a blowout is base case
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
August 3, 2023 4:05 PM EDTNet cash used in operating and investing activities was $45.7 million in the second quarter and $93.2 million for the first six months of 2023; quarter-end cash and restricted cash position was $661.3 million Revised year-end cash guidance to be approximately $600 million in cash, cash equivalents and restricted cash, representing an increase of $88 million from prior guidance of $512 million Presented research across multiple Alzheimers disease programs targeting amyloid-beta and tau at AAIC 2023, including data on PRX012, PRX005 and PRX123 Bristol Myers Squibb (BMS) obtained the $55 million exclusive worldwide license to PRX005 in July, expanding on the... More
